Peer AI, a leading agentic AI platform transforming regulatory documentation for the life sciences industry, announced it has secured $12.1 million in total funding, led by Flare Capital Partners and SignalFire, to accelerate product development and commercial expansion.

This investment signals a major move into the estimated $15 billion market for regulatory documentation, which remains a critical bottleneck in drug development, where manual processes lead to high rejection rates (nearly 75%) and delays averaging 435 days for applications like the more than 1,500 documents and 200,000 pages required for a new drug. Peer AI addresses this challenge by deploying purpose-built, domain-specific AI agents combined with an intuitive user interface, allowing expert medical writers to apply their subject matter expertise at strategic control points during documentation workflows.

Top pharmaceutical companies and emerging biotechs using the platform are demonstrating strong adoption, achieving drafting time reductions ranging from 55% to 94%, cutting the time for clinical study report (CSR) drafting from 40 days to 17, and reducing protocol turnaround from 6–8 weeks to just one week, all while maintaining strict regulatory compliance, consistency, and accuracy. The platform utilizes multiple specialized agents—including data source, authoring, style, and post-processing agents—to automate the creation of complex documents such as protocols, CSRs, and IND applications, allowing experts to focus on quality control and validation. Ultimately, the company’s vision, championed by CEO Anita Modi, is to create an intelligent regulatory workflow that connects documentation, data, and decision-making to significantly speed up drug approvals and accelerate life-changing treatments to patients worldwide.